Flow cytometry allows rapid detection of protein aggregates in cell culture and zebrafish models of spinocerebellar ataxia-3
Katherine J. RobinsoniD, Madelaine C. Tym, Alison L. HoganiD, Maxinne WatchoniD, Kristy C. YuaniD, Stuart K. PlenderleithiD, Emily K. DoniD, Angela S. LairdiD
Abstract
Spinocerebellar ataxia-3 (SCA3, also known as Machado Joseph Disease), is a neurodegenerative disease caused by inheritance of a ATXN3 gene containing a CAG repeat expansion, resulting in presence of a polyglutamine (polyQ) repeat expansion within the encoded human ataxin-3 protein. SCA3 is characterized by the formation of ataxin-3 protein aggregates within neurons, neurodegeneration, and impaired movement. In this study we have identified protein aggregates in both neuronal-like (SHSY5Y) cells and in vivo (transgenic zebrafish) models expressing human ataxin-3 protein containing polyQ expansion. We have adapted a flow cytometric methodology, allowing rapid quantification of detergent insoluble forms of ataxin-3 fused to a green fluorescent protein. Flow cytometric analysis revealed an increased number of detergent-insoluble ataxin-3 particles in cells and zebrafish expressing polyQ expanded ataxin-3 when compared to cells and zebrafish expressing wildtype human ataxin-3. Interestingly, a protein aggregation phenotype could be detected as early as two days of age in transgenic zebrafish, prior to the onset of a detectable movement impairment at 6 days of age, suggesting protein aggregation may be an early disease phenotype in SCA3. Further, treatment of SCA3 cells and transgenic zebrafish with compounds known to modulate the activity of the autophagy protein quality control pathway altered the number of detergent-insoluble ataxin-3 particles detected by flow cytometry. We conclude that flow cytometry is a powerful tool that can be harnessed to rapidly quantify ataxin-3 aggregates, both in vitro and in vivo, and can be utilised to screen and compare potential protein aggregate targeting therapies.
02 /Specification & Classification
Click any tag to browse matching papers- Citations
- 10
- FWCI
- 0.92
- Field percentile
- top 32%
- Organism
- Assay
- Research Focus
- Approach
Reproducibility ledger
Nobody has reported trying to reproduce this paper yet. Did you replicate an experiment or run the code? Your report saves the next lab a week.
Sign in to file a reproducibility report.
Related papers
- Treatment with sodium butyrate induces autophagy resulting in therapeutic benefits for spinocerebellar ataxia type 3
Maxinne Watchon, Katherine J. Robinson, … Angela S. Laird·The FASEB JournalPeer-reviewed·Jan 23, 2024
- Druggable genome screen identifies new regulators of the abundance and toxicity of ATXN3, the Spinocerebellar Ataxia Type 3 disease protein
Naila S. Ashraf, Joanna R. Sutton, … Maria do Carmo Costa·Neurobiology of DiseasePeer-reviewed·Nov 26, 2019
- A novel Ataxin-3 knock-in mouse model mimics the human SCA3 disease phenotype including neuropathological, behavioral, and transcriptional abnormalities
Eva Haas, Rana Dilara Incebacak Eltemur, … Jeannette Hübener‐Schmid·bioRxiv·Feb 28, 2020
- Autophagosome-tethering compounds selectively lower mutant ataxin-3 in preclinical models of spinocerebellar ataxia type 3
Hongyu Yuan, Zhao Chen, … Hong Jiang·bioRxiv·Oct 8, 2026
- Age-dependent somatic expansion of the ATXN3 CAG repeat in the blood and buccal cell DNA of individuals with spinocerebellar ataxia type 3
Ahmed M. Sidky, Ana Rosa Vieira Melo, … Darren G. Monckton·medRxiv·Mar 13, 2024
- Regional and age-dependent changes in ubiquitination in cellular and mouse models of Spinocerebellar ataxia type 3
Haiyang Luo, Sokol V. Todi, … Maria do Carmo Costa·Frontiers in Molecular NeurosciencePeer-reviewed·Apr 14, 2023